Gilead Sciences, Inc.

NASDAQ:GILD

Drug Manufacturers - General

Healthcare
$168.98 -2.14%

-$2.69 today

Market cap
$209.59B
Beta
0.33
P/E (TTM)
16.5
EPS (TTM)
$7.42
Dividend yield
2.62%
52W Low $104.46High $157.29

Volume 4.82M

Average 6.78M

GILD Interest Income

Income earned on cash, deposits, and investments held by the company.

Gilead Sciences, Inc.NASDAQ: GILD

Interest Income · Q2 FY2026 · quarter ended Jun 2026

Interest income remains negative

Q2 FY2026 interest income was $0, compared with $73M a year earlier. Trailing-twelve-month interest income was $183M. Over 3 fiscal years it compounded at +48.8% a year.

Context

  • Interest income amounted to 1.2% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly interest income holds near $0 or moves back toward the trailing-twelve-month quarterly average of $45.75M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$349M+24.2% YoY
LTMJun 2026
$183M-39.8% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+24.2%——
3-year CAGR+48.8%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
349M USD
Year-over-year change
+24.2%

Interest Income vs competitors

How GILD compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -39.8% is the 6th highest of 9, against a peer median of -35.8%.
  • Interest income amounts to 0.6% of revenue for GILD, versus a peer median of 0.3%.
GILD Competitors
Interest Income for GILD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$685M USD-37.7%+29.2%0.7%
PFEPfizer Inc.LTM Jun 2026$532M USD-9.1%+33.9%0.8%
AZNAstraZeneca PLCLTM Sep 2026$342.11M USD+13.7%+64.4%0.6%
SNYSanofiLTM Jun 2026€274.69M EUR-50.8%+25.1%0.6%
MRKMerck & Co., Inc.LTM Jun 2026$200M USD-55.7%+29.8%0.3%
ABBVAbbVie Inc.LTM Sep 2026$198M USD-33.8%+12.7%0.3%
GILDGilead Sciences, Inc.LTM Jun 2026$183M USD-39.8%+48.8%0.6%
GSKGSK plcLTM Jun 2026£106M GBP+24.7%-4.5%0.3%
LLYEli Lilly and CompanyLTM Jun 2026$65M USD-64.0%+34.6%0.1%
NVSNovartis AGLTM Jun 2026$0 USD—-0.2%0.0%
Peer median (excluding GILD) —-35.8%+29.2%0.3%

Competitors are the stored peer set for GILD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.31B27.28B27.12B28.75B29.44B
Cost of Revenue6.6B5.66B6.5B6.25B6.23B
Gross Profit20.7B21.62B20.62B22.5B23.21B
Gross Margin75.8%79.3%76.0%78.3%78.8%
Research & Development4.6B4.98B5.72B5.91B5.8B
Selling, General & Admin5.25B5.67B6.09B6.09B5.71B
Operating Expenses10.79B14.29B13.01B20.84B11.51B
Depreciation & Amortization2.05B2.1B2.69B2.77B2.76B
EBITDA11.33B8.85B10.5B4.43B13.58B
EBITDA Margin41.5%32.4%38.7%15.4%46.1%
Operating Income9.92B7.33B7.61B1.66B11.7B
Operating Margin36.3%26.9%28.0%5.8%39.7%
Interest Income0106M376M281M349M
Interest Expense1B935M944M977M1.02B
Other Income / Expenses(1.64B)(1.52B)(746M)(972M)(1.91B)
Income Before Tax8.28B5.81B6.86B690M9.8B
Pre-Tax Margin30.3%21.3%25.3%2.4%33.3%
Income Tax Expense2.08B1.25B1.25B211M1.29B
Net Income6.23B4.59B5.67B480M8.51B
Net Margin22.8%16.8%20.9%1.7%28.9%
EPS (Basic)4.963.664.540.386.84
EPS (Diluted)4.933.644.500.386.78
Weighted Avg Shares1.26B1.26B1.25B1.25B1.24B
Weighted Avg Shares (Diluted)1.26B1.26B1.26B1.26B1.26B

Gilead Sciences, Inc.

NASDAQ:GILD

Intrinsic Alpha fair value

Locked

Current Price

$168.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.